Affiliation:
1. Division of Clinical Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju 28160, Chungcheongbuk-do, Republic of Korea
Abstract
During the emergence of infectious diseases, evaluating the efficacy of newly developed vaccines requires antigen proteins. Available methods enhance antigen protein productivity; however, structural modifications may occur. Therefore, we aimed to construct a novel transient overexpression vector capable of rapidly producing large quantities of antigenic proteins in mammalian cell lines. This involved expanding beyond the exclusive use of the human cytomegalovirus (CMV) promoter, and was achieved by incorporating a transcriptional enhancer (CMV enhancer), a translational enhancer (woodchuck hepatitis virus post-transcriptional regulatory element), and a promoter based on the CMV promoter. Twenty novel transient expression vectors were constructed, with the vector containing the human elongation factor 1-alpha (EF-1a) promoter showing the highest efficiency in expressing foreign proteins. This vector exhibited an approximately 27-fold higher expression of enhanced green fluorescent protein than the control vector containing only the CMV promoter. It also expressed the highest level of severe acute respiratory syndrome coronavirus 2 receptor-binding domain protein. These observations possibly result from the simultaneous enhancement of the transcriptional activity of the CMV promoter and the human EF-1a promoter by the CMV enhancer. Additionally, the synergistic effect between the CMV and human EF-1a promoters likely contributed to the further enhancement of protein expression.
Funder
Korea National Institute of Health, Korea Disease Control and Prevention Agency
Reference40 articles.
1. Trends in recombinant protein use in animal production;Gifre;Microb. Cell Factories,2017
2. Vaccine development for emerging infectious diseases;Excler;Nat. Med.,2021
3. The lightning-fast quest for COVID vaccines—And what it means for other diseases;Ball;Nature,2021
4. Balawejder, F., Sampson, S., and Stratton, T. (2024, February 12). Industrial Strategy Council Home Page. Available online: https://industrialstrategycouncil.org/lessons-industrial-policy-development-oxfordastrazeneca-covid-19-vaccine.
5. Protein post-translational modification in SARS-CoV-2 and host interaction;Cheng;Front. Immunol.,2022